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Abstract
Background: Chronic kidney disease (CKD) poses a major health threat to people living in low- and middle-income
countries, especially when it is combined with HIV, antiretroviral treatment (ART) or communicable and non-
communicable diseases. Data about the prevalence of CKD and its association with other diseases is scarce,
particularly in HIV-negative individuals. This study estimated the prevalence of CKD in individuals who were either
HIV-positive (and ART-naïve) or HIV-negative in an urban Malawian population.
Methods: This cross-sectional study was conducted at a HIV Testing and Counselling Centre in Lilongwe, Malawi.
Consecutive clients who were ≥18 years and consented to participate were enrolled over a 3-month period. Clients
were screened for potential renal disease and other conditions. Their blood pressure was measured, urine examined
via dipstick and albumin/creatinine ratio and blood drawn for creatinine, cystatin C and sero-markers for schistosomiasis.
Estimated glomerular filtration (eGFR) rate was calculated using a cystatin C-based formula and classified according to
the matching CKD stages by K/DOQI (The National Kidney Foundation Kidney Disease Outcome Quality Initiative). We
performed a descriptive analysis and compared differences between HIV-positive (and ART naïve) and -negative
participants.
Results: Out of 381 consecutive clients who were approached between January and March 2012, 366 consented and
363 (48% female; 32% HIV-positive) were included in the analysis. Reasons for exclusion were missing samples or
previous use of ART. HIV-positive and negative clients did not differ significantly with regard to age, sex or medical
history, but they did differ for BMI—21.3 (±3.4) vs. 24 (±5.1), respectively (p < 0.001). Participants also differed with regard
to serum cystatin C levels, but not creatinine. Reduced kidney function (according to CKD stages 2–5) was significantly
more frequent 15.5 vs. 3.6%, respectively (p < 0.001) among HIV-positive clients compared to the HIV-negative group.
Differences in renal function were most pronounced in the eGFR range 60–89 ml/min/1.73 m2 accompanied by
proteinuria with results as 11.2% vs. 1.2%, respectively for clients who were HIV-positive vs. HIV-negative (p = 0.001).
Conclusions: Reduced glomerular filtration and/or proteinuria occurred in 15.5% of HIV-positive, and 3.6% of
HIV-negative patients in this urban Malawian cohort.
Since generalized renal monitoring is not feasible in Malawi or other resource-limited countries, strategies to identify
patients at risk for higher stages of CKD and appropriate preventive measures are needed for both HIV-positive
and HIV-negative patients.
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Background
Chronic kidney disease (CKD) is categorized as a non-
communicable disease (NCD), a group that includes
several globally prioritized diseases including diabetes,
chronic respiratory disease, cancer and cardiovascular
disease. NCDs account for 60% of all deaths worldwide,
and 80% occur in low- and middle-income countries
(LMIC) [1, 2], which underlines the assumption that
NCDs are associated with poverty [3]. CKD increases
the risk for developing hypertension and cardiovascular
disease and also exacerbates the course of these illnesses.
CKD occurs more frequently in patients with hyperten-
sion, cardiovascular disorders or diabetes [4].
The consequences of CKD are hypothesized to be worse
in LMIC because of the high burden of non-communicable
and communicable diseases, such as HIV infection and
tuberculosis as well as infectious tropical diseases coupled
with limited access to health care facilities for routine
screening [5–7]. Calculations suggest that approximately
200–300 individuals per million are affected by CKD in
sub-Saharan Africa (SSA) [8].
HIV is highly prevalent in SSA and constitutes an in-
dependent risk factor for kidney disease due to the direct
and indirect effects of the infection, e.g., HIV-associated
nephropathy (HIVAN). Diseases associated with HIV-
infection (e.g., schistosomiasis or tuberculosis) can also
play an important role in a patient developing CKD [9].
Additionally, drugs used in antiretroviral treatment (ART)
such as tenofovir disoproxile fumarate (TDF) can affect renal
function, especially in people with underlying CKD [10].
Despite a high HIV-prevalence of approximately 11%
in Malawi [11] and the associated risks for CKD, current
knowledge about the prevalence of CKD or renal dis-
eases in SSA countries including Malawi is scarce and
renal registries are non-existent. In the existing literature
findings on the prevalence of CKD in SSA range from
4.7% in a HIV-negative cohort in Uganda [12] to 33.5%
in HIV-positive people in Zambia [13]. It is not easy to
determine whether these differences resulted from actual
differences in prevalence, varying thresholds and CKD
definitions, or if they were influenced by the inability to
compare the various equations and laboratory methods
used to assess kidney function in SSA [14].
This cross-sectional descriptive study estimated the
prevalence of renal impairment in an adult urban
Malawian population of HIV-positive (and ART naïve)
and HIV–negative individuals. We also describe the preva-
lence of potential risk factors for CKD in HIV-positive pa-
tients before the use of TDF in first line ART.
Methods
A cross-sectional study was performed at the HIV Testing
and Counselling (HTC) centre at the Lighthouse HIV
clinic (two centres) in Lilongwe, Malawi between the 24th
of January 2012 and the 29th of March 2012. The Light-
house serves a mainly urban population of approxi-
mately 670,000 people living among a larger population
of 1,230,000 people in Lilongwe [15].
All clients who were ≥18 years of age and ART-naïve,
who came for HTC at the Lighthouse centre during the
study period were approached to enrol. After providing
informed consent, a standardized questionnaire about
age, gender, HIV-status, possible pregnancy, current symp-
toms and medical and family history was completed. Body
height and weight were taken. Blood pressure (BP) was
measured using a calibrated standard automatic BP device
(Omron, Germany). It was used on the free right arm at
heart level. Clients sat for at least 10min with their backs
touching the chair backrest [16]. Hypertension was defined
as history of hypertension, use of antihypertensive medica-
tion or BP values ≥ 140 systolic or ≥ 90 diastolic. Data were
excluded if samples were missing or there was a history of
using ART. The study methodology has been described in
detail elsewhere [16]. The dataset used for this article can
be found in Additional file 1.
Laboratory measurements
Venous blood (5 ml) and a midstream-urine sample
were collected. An aliquot of serum and one of urine were
frozen at −80 °C within 6 hours after performing dipstick,
centrifugation and microscopy. If there was a positive
protein patch or a positive haemoglobin/erythrocytes
patch on the dipstick, urine microscopy was performed.
Analyses for serum creatinine, serum cystatin C and
urine albumin-creatinine-ratio (ACR) were performed
at the University of Heidelberg, Germany (samples were
sent on dry ice by air). Creatinine levels in serum and
urine were photometrically analysed; cystatin C and
urine albumin were assessed by a turbidimetric method
(ADVIA 2400 Siemens Healthcare Diagnostics) [16].
Schistosomiasis serology was performed at a reference
laboratory for schistosomiasis in the Department of
Clinical Tropical Medicine at the University of Heidelberg.
Schistosoma-egg-based ELISA and parenchymal and focal
indirect immunofluorescence assays were used. Results
were classified into positive, borderline or negative ac-
cording to lab standards.
Assessment of renal function
A cystatin C-based estimated glomerular filtration rate
(eGFR) was calculated using the formula of Van Deventer
et al. developed in a comparable cohort in South Africa
[17] and applied in the final analysis. For comparison, we
also calculated eGFR with the Cockcroft-Gault equation
as elaborated in Glaser et al. [16]. Renal function was clas-
sified according to K/DOQI eGFR categories for CKD
[18] and kidney damage was defined as proteinuria with
an albumin-creatinine ratio > 3 mg/mmol creatinine.
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Statistical analysis
Data entry was done in MS Access 2007 and analysed
with STATA 10 and 11. Significance in the differences
between HIV-positive and -negative participants as well
asassociations were tested using a t-test and chi-squared
test according to the underlying distribution and a
Spearman’s test for correlation; the level of significance
was set at p > 0.05 [16].
Ethical clearance
The study protocol received clearance by the ethical com-
mittee of the University of Heidelberg and the National
Health Sciences Research Committee of Malawi.
Results
Out of 381 consecutive clients invited to participate, 366
consented and 363 (48% female) were included in the
final analysis. Reasons for exclusion were missing sam-
ples or previous ART treatment. Of the included partici-
pants, 116 (32%) and 247 (68%) were HIV-positive and
HIV-negative, respectively. Eight women were pregnant
and 13 were breastfeeding. Ages ranged from 19 to
69 years. The mean BMI was 23.2 (SD = 4.8), but was
significantly lower in HIV-positive compared to HIV-
negative individuals: 21.3 (SD = 3.4) vs. 24.0 (SD = 5.10),
respectively (p < 0.001). Mean serum cystatin C was
0.82 mg/l (SD = 0.23), and differed significantly between
HIV-positive and –negative participants: 0.90 mg/l (SD =
0.18) and 0.79 mg/l (SD = 0.24) respectively (p < 0.001).
Elevated BP was defined as ≥140 systolic or ≥90 diastolic
and was found in 49 (14%) participants, (40 HIV-negative,
9 HIV-positive; p = 0.028). Fifteen participants (4%) re-
ported having had an earlier diagnosis of diabetes mellitus
and one participant was diagnosed with diabetes mellitus
during this study (Table 1).
Urine samples from 71 patients were examined with a
microscope; 21 (29.6%) had bacteriuria, 3 (4.2%) had
trichomonas and 4 (5.6%) had schistosoma haemato-
bium eggs.
Schistosoma-antibody ELISA and indirect immuno-
fluorescent assay testing were performed and 123 partic-
ipants (34%) were found to have positive serology
indicating recent or past infection with either schistosoma
haematobium or schistosoma mansoni.
Three participants reported having previous kidney
diseases. One reported having had glomerulonephritis,
while the other two could not specify their disease.
Although a total of 47 (13%) participants suffered from
renal impairment, and 11 (3.1%) had moderate to severe
renal dysfunction, none of those had had a previous diag-
nosis of kidney disease.
CKD (stages 1–5) was significantly more common in
HIV-positive individuals: 15.5% of HIV-positive vs. 3.6%
of HIV-negative participants (p < 0.001). Proteinuria and
HIV were also significantly associated (p = 0.001)
(Table 2).
Table 1 Patient characteristics of the participants of the RESULT study conducted at the Lighthouse Clinic in urban Lilongwe,
Malawi between January and March 2012
Total Mean (SD) or N (% of total), N = 363 HIV+ (%), N = 127 HIV- (%), N = 247 p value
Age 34.1 (±10.9) 33.9 (±9.3) 34.2 (±11.6) 0.81*
Sex
Women 174 (48%) 57 (49%) 117 (47%) 0.75**
Men 189 (52%) 59 (51%) 130 (53%)
BMI 23.2 (±4.8) 21.3 (±3.4) 24. (±5.10) <0.001*
Serum creatinine (mg/dl) 0.76 (±0.31) 0.74 (±0.21) 0.78 (±0.34) 0.21*
Serum cystatin C (mg/L) 0.82 (±0.23) 0.90 (±0.18) 0.79 (±0.24) <0.001*
eGFR by cystatin C 96.39 (±15.61) 90.87 (±14.75) 98.98 (±15.36) <0.001*
Proteinuria
ACR > 3 mg/mmol 44 (12.1%) 24 (20.7%) 20 (8.1%) 0.001**
No 319 (87.9%) 92 (79.3%) 227 (91.9%)
BP ≥ 140 systolic or
≥ 90 diastolic 49 (13.5%) 9 (7.8%) 40 (16.2%) 0.028**
No 314 (86.5%) 107 (92.2%) 207 (83.8%)
Schistosomiasis
Positive (IIFT > 1:40 or ELISA ODa >3) 123 (33.9%) 34 (29.3%) 89 (36%) 0.379**
Negative or borderline 240 (66.1%) 82 (70.7%) 158 (63.9%)
*t-test; **χ2 test
aIIFT indirect immunofluorescent assay, ELISA enzyme-linked immunosorbent assay optical density
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Higher age (age groups: 18–30, 30–45 and >45 years)
and higher stages of CKD (CKD stage 2–5, (p < 0.001)
and CKD stage 3–5, (p < 0.001), respectively) were asso-
ciated. Testing with Spearman’s test of correlation led to
the same result: CKD stage 2–5 (p < 0.001), rho = 0.22;
CKD 3–5 (p = 0.001), rho = 0.21. CKD stage 3–5 was
also significantly associated with male gender (p = 0.045)
and hypertension (p = 0.009) (defined as systolic BP ≥ 140
or diastolic BP ≥ 90 mmHg either measured or reported).
Although diabetes and higher stages of CKD showed a
trend toward association, there was no statistical signifi-
cance. Nor was there any significant association of CKD
and schistosomiasis.
Discussion
The general prevalence of CKD stage 2–5 in the study
group was 7.5% with 3.1% suffering from moderate to
severe impairment corresponding to CKD stages 3–5.
We found a significant difference between HIV-positive
and –negative individuals regarding reduced eGFR. HIV-
status, age and hypertension were associated with CKD.
Our study found a lower prevalence of reduced eGFR
in HIV-positive (15.5%) than a study conducted in Blan-
tyre in 2009, where 57.4% of the participants with WHO
clinical stage I or II for HIV [19] presented with a re-
duced creatinine clearance of <90 ml/min [20]. This
study estimated GFR using the Cockcroft-Gault formula,
which we also did in a sensitivity analysis as elaborated
in Glaser et al. [16]. The difference cannot be explained
by the use of various formulas alone, nor can it be ex-
plained by creatinine determination or composition of
the cohorts since we did not exclude patients with more
advanced stages of HIV infection. Therefore, this discrep-
ancy in findings warrants further investigation. As ex-
pected, higher stages of CKD in our study were associated
with an older age [21]. This was also true for hypertension,
which is known to be one of the main risk factors for
CKD [22]. Due to the small number of participants with
diabetes (another established risk factor for CKD), we
were unable to confirm an association with CKD.
Proteinuria was very common in HIV-positives, which
is also supported by other studies [23]. Although espe-
cially heavy proteinuria [24] is known to occur in HIVAN
[25], we did not often find HIVAN in the HIV-positive
group.
The prevalence of serological markers for past or recent
schistosomiasis infection was higher than expected among
this adult study cohort. Despite the fact that schistosomia-
sis is a known risk factor for developing CKD [26] or ac-
quiring HIV [27], we did not find a significant association
in either case.
Levels of elevated BP were found to be much lower
(13.5%) in this study than in the Malawi STEP survey of
2009 where elevated BP (diastolic BP ≥ 90 mmHg or
systolic ≥ 140 mmHg or on medication) was found in
32.9% [28]. This difference in BP levels warrants further
investigation since intuitively one would assume that
HIV testing leads to higher BP levels.
The study has several limitations. Due to limited la-
boratory facilities and the study protocol, we did not use
an acknowledged gold-standard method to assess GFR.
After studying the literature, we decided to use cystatin
C measurement as a quasi-gold standard, because is it
less dependent on muscle mass and appears to show the
best results in HIV-positive individuals [29] including
those in SSA [17]. At the time of this study, the certified
reference material developed by the International Feder-
ation of Clinical Chemistry and Laboratory Medicine
(IFCC) and recommended by KDIGO in 2012 [30], had
not yet been introduced and therefore, was not used.
However, analysis was performed at the University of
Heidelberg laboratory, thus fulfilling the highest quality
control standards.
Due to the cross-sectional character of the study, it
was not possible to collect kidney markers over a period
Table 2 Participants of the RESULT study, conducted in Lilongwe Malawi and listed according to CKD stages as defined by K/DOQI
[20] and HIV status
Kidney function (eGFR in ml/min/1.73 m2) Total, n = 363 (%) HIV-positive, n = 116 (%) HIV-negative, n = 247 (%)
Stage 0: No impairment:
eGFR≥ 60, − proteinuria 316 (87) 90 (77.6) 226 (91.5)
Stage 1: Kidney damage with normal or ↑GFR:
eGFR≥ 90 + proteinuria 20 (5.5) 8 (6.9) 12 (4.9)
Stage 2: Kidney damage with mild ↓ GFR:
eGFR 60–89 + proteinuria 16 (4.4) 13 (11.2) 3 (1.2)
Stage 3: Moderate ↓ GFR:
eGFR 30–59 ± proteinuria 9 (2.5) 5 (4.3) 4 (1.6)
Stage 4: Severe ↓ GFR:
(eGFR 15–29 ± proteinuria) 2 (0.6) - 2 (0.8)
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of three months as normally required for a final CKD
diagnosis [18]. Instead, we collected kidney markers once
during the study. However, most studies investigating
CKD prevalence also use a one-time-only evaluation of
GFR, e.g., the US Renal Data System Report in 2012 [31].
Our study population was not representative of the
general adult Malawian population. Since the study site
was urban HTC centre, we recruited more HIV-positive
individuals compared to the national prevalence of HIV.
This might have also led to a bias among HIV-negative
participants, since individuals who felt sick, suspected
that they had an HIV-infection and sought testing at the
HTC, thus resulting in more patients who were sick, but
still HIV-negative than in the general population.
Lastly the cross-sectional character of the study did not
allow for a prognosis of whether or not the renal function
of patients who were HIV-positive would improve with
ART [32].
Although the CKD prevalence of our study-population
was lower than in the aforementioned Blantyre study per-
formed in 2009, the results of this study underline the pub-
lic health importance of CKD. The prevalence of impaired
renal function seems to be higher in HIV-positive individ-
uals even though the most advanced stages of reduced
eGFR occurred in two HIV-negative individuals in our
study. Despite the small number the finding could reflect
the problem of late presentation and the lack of diagnosis
of renal impairment in the Malawian health care system.
A particular strength of this study was that it also ex-
amined eGFR in HIV-negative individuals who are less
frequently described in scientific literature concerning
CKD in SSA compared to HIV-positive patients.
Conclusion
Our study confirms that there is a higher prevalence of
CKD in HIV-positive individuals in Malawi, however the
rate is less pronounced than previously reported in a 2009
study. The limited resources in countries like Malawi pre-
clude general renal screening even in HIV-positive pa-
tients prior to the initiation of ART. Therefore, an easy-
to-use risk score for targeted screening would be desirable
to identify and monitor the renal function of patients with
a high risk for CKD. Finally, longitudinal data from set-
tings like Malawi with a differentiated assessment of the
type of renal disease are urgently needed.
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